Eighteen patients with advanced ovarian cancer not or no longer responding to cisplatinum and epidoxorubicin including combination chemotherapy were retreated with the above two drugs in combination with lonidamine and interferon, administered with the aim of restoring chemosensitivity. Overall response rate was 32%, with one durable complete response and four partial responses. Toxicity was quite manageable, myalgia being the main additional toxic effect with respect to those reported with conventional chemotherapy. Our study emphasizes the need for additional trials with agents able to overcome drug resistance, which is the chief determinant of treatment failure in advanced ovarian cancer.
Recovery of sensitivity to cisplatinum and epidoxorubicin by ionidamine and interferon in advanced ovarian-cancer / Iaffaioli, R; Tortoriello, A; Facchini, G; Caponigro, F; Mastrantonio, P; Barzelloni, M; Gesue, G; Mantovani, G; Santangelo, Michele. - In: INTERNATIONAL JOURNAL OF ONCOLOGY. - ISSN 1019-6439. - STAMPA. - 4:6(1994), pp. 1265-1269.
Recovery of sensitivity to cisplatinum and epidoxorubicin by ionidamine and interferon in advanced ovarian-cancer.
SANTANGELO, MICHELE
1994
Abstract
Eighteen patients with advanced ovarian cancer not or no longer responding to cisplatinum and epidoxorubicin including combination chemotherapy were retreated with the above two drugs in combination with lonidamine and interferon, administered with the aim of restoring chemosensitivity. Overall response rate was 32%, with one durable complete response and four partial responses. Toxicity was quite manageable, myalgia being the main additional toxic effect with respect to those reported with conventional chemotherapy. Our study emphasizes the need for additional trials with agents able to overcome drug resistance, which is the chief determinant of treatment failure in advanced ovarian cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
